Information between 6th January 2026 - 16th January 2026
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
| Division Votes |
|---|
|
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context Alison Hume voted Aye - in line with the party majority and in line with the House One of 323 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 348 Noes - 167 |
|
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context Alison Hume voted No - in line with the party majority and in line with the House One of 325 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 181 Noes - 335 |
|
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context Alison Hume voted Aye - in line with the party majority and in line with the House One of 328 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 344 Noes - 173 |
|
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context Alison Hume voted No - in line with the party majority and in line with the House One of 334 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 187 Noes - 351 |
|
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context Alison Hume voted No - in line with the party majority and in line with the House One of 328 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 172 Noes - 334 |
|
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context Alison Hume voted No - in line with the party majority and in line with the House One of 321 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 184 Noes - 331 |
|
12 Jan 2026 - Finance (No. 2) Bill - View Vote Context Alison Hume voted No - in line with the party majority and in line with the House One of 338 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 167 Noes - 350 |
|
12 Jan 2026 - Finance (No. 2) Bill - View Vote Context Alison Hume voted No - in line with the party majority and in line with the House One of 333 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 188 Noes - 341 |
|
12 Jan 2026 - Finance (No. 2) Bill - View Vote Context Alison Hume voted Aye - in line with the party majority and in line with the House One of 336 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 344 Noes - 181 |
|
12 Jan 2026 - Finance (No. 2) Bill - View Vote Context Alison Hume voted No - in line with the party majority and in line with the House One of 336 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 185 Noes - 344 |
|
14 Jan 2026 - Public Order - View Vote Context Alison Hume voted Aye - in line with the party majority and in line with the House One of 295 Labour Aye votes vs 26 Labour No votes Tally: Ayes - 301 Noes - 110 |
|
12 Jan 2026 - Clause 1 - View Vote Context Alison Hume voted No - in line with the party majority and in line with the House One of 332 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 188 Noes - 341 |
|
12 Jan 2026 - Clause 1 - View Vote Context Alison Hume voted No - in line with the party majority and in line with the House One of 338 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 167 Noes - 350 |
|
12 Jan 2026 - Clause 1 - View Vote Context Alison Hume voted No - in line with the party majority and in line with the House One of 335 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 185 Noes - 344 |
|
12 Jan 2026 - Clause 1 - View Vote Context Alison Hume voted Aye - in line with the party majority and in line with the House One of 335 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 344 Noes - 181 |
| Speeches |
|---|
|
Alison Hume speeches from: Business of the House
Alison Hume contributed 1 speech (78 words) Thursday 15th January 2026 - Commons Chamber Leader of the House |
| Written Answers |
|---|
|
Genomics
Asked by: Alison Hume (Labour - Scarborough and Whitby) Friday 9th January 2026 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, what plans her Department has to support the use of combinatorial genomic analysis techniques, such as those used by Precision Life to identify novel ME genetic associations, within government-funded research programmes. Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), funds a broad portfolio of health research, including researcher led proposals using combinatorial genomic analysis. MRC has prioritised research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) for many years, investing over £4.65 million since 2020, and continues to welcome high quality applications in this area. UKRI supports collaboration between Government funded bodies and private sector researchers across its councils and Innovate UK. This includes funding the LOCOME study led by Precision Life, through Innovate UK’s Advancing Precision Medicine programme, which supports the development of digital and data tools to improve diagnosis and treatment. MRC also enables academic-industry partnerships through its Industry Collaboration Framework. UKRI does not typically maintain disease‑specific research strategies, instead providing open funding routes for the most impactful research across disciplines. Targeted work can be supported where needed. For example, in 2020, the National Institute for Health and Care Research (NIHCR), the Scottish Government and MRC funded the James Lind Alliance Priority Setting Partnership to identify ME/CFS research priorities. |
|
Genomics
Asked by: Alison Hume (Labour - Scarborough and Whitby) Friday 9th January 2026 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, what plans her Department has to develop a long-term research strategy into under-researched health conditions that reflects the scale of emerging genetic evidence identified by private-sector research organisations, including Precision Life’s LOCOME study. Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), funds a broad portfolio of health research, including researcher led proposals using combinatorial genomic analysis. MRC has prioritised research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) for many years, investing over £4.65 million since 2020, and continues to welcome high quality applications in this area. UKRI supports collaboration between Government funded bodies and private sector researchers across its councils and Innovate UK. This includes funding the LOCOME study led by Precision Life, through Innovate UK’s Advancing Precision Medicine programme, which supports the development of digital and data tools to improve diagnosis and treatment. MRC also enables academic-industry partnerships through its Industry Collaboration Framework. UKRI does not typically maintain disease‑specific research strategies, instead providing open funding routes for the most impactful research across disciplines. Targeted work can be supported where needed. For example, in 2020, the National Institute for Health and Care Research (NIHCR), the Scottish Government and MRC funded the James Lind Alliance Priority Setting Partnership to identify ME/CFS research priorities. |
|
Chronic Fatigue Syndrome: Research
Asked by: Alison Hume (Labour - Scarborough and Whitby) Friday 9th January 2026 Question to the Department for Science, Innovation & Technology: To ask the Secretary of State for Science, Innovation and Technology, what mechanisms are in place to support collaboration between Government-funded bodies and private-sector researchers following the identification of multiple biological pathways implicated in ME by the LOCOME study. Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology) The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), funds a broad portfolio of health research, including researcher led proposals using combinatorial genomic analysis. MRC has prioritised research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) for many years, investing over £4.65 million since 2020, and continues to welcome high quality applications in this area. UKRI supports collaboration between Government funded bodies and private sector researchers across its councils and Innovate UK. This includes funding the LOCOME study led by Precision Life, through Innovate UK’s Advancing Precision Medicine programme, which supports the development of digital and data tools to improve diagnosis and treatment. MRC also enables academic-industry partnerships through its Industry Collaboration Framework. UKRI does not typically maintain disease‑specific research strategies, instead providing open funding routes for the most impactful research across disciplines. Targeted work can be supported where needed. For example, in 2020, the National Institute for Health and Care Research (NIHCR), the Scottish Government and MRC funded the James Lind Alliance Priority Setting Partnership to identify ME/CFS research priorities. |
|
Chronic Fatigue Syndrome and Long Covid: Health Services
Asked by: Alison Hume (Labour - Scarborough and Whitby) Wednesday 14th January 2026 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, whether his Department will be assessing the impact of new developments in Myalgic Encephalomyelitis and Long Covid research, such as the findings of the LOCOME project, on health policy towards those living with long term health conditions. Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care) On 6 November, the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) jointly hosted a showcase event for post-acute infection conditions research, which included a review of the DecodeME research project and the PrecisionLife study on myalgic encephalomyelitis (ME) and long COVID research. PrecisionLife is leading on the LOCOME, or LOng COvid and Myalgic Encephalomyelitis Diagnostics Stratification, project. The showcase event was attended by speakers from a range of disciplines, including researchers, people with lived experience, ME charities, NIHR and MRC representatives, as well as Government officials. The Department is always very keen to reflect newly emerging research findings in its policy-making. |
| MP Financial Interests |
|---|
|
5th January 2026
Alison Hume (Labour - Scarborough and Whitby) 1.1. Employment and earnings - Ad hoc payments Payment received on 18 November 2025 - £216.53 Source |
| Select Committee Documents |
|---|
|
Tuesday 13th January 2026
Oral Evidence - 2026-01-13 16:15:00+00:00 Proposals for backbench debates - Backbench Business Committee Found: the meeting Members present: Bob Blackman (Chair); Jonathan Davies; Mr Lee Dillon; Mary Glindon; Alison Hume |
|
Monday 12th January 2026
Special Report - 7th Special Report - Airport expansion and climate and nature targets: Government Response Environmental Audit Committee Found: Conservative; Bognor Regis and Littlehampton) Chris Hinchliff (Labour; North East Hertfordshire) Alison Hume |
| Calendar |
|---|
|
Tuesday 13th January 2026 4 p.m. Backbench Business Committee - Oral evidence Subject: Proposals for backbench debates At 4:15pm: Oral evidence Members of Parliament - Members of Parliament at House of Commons View calendar - Add to calendar |
|
Tuesday 20th January 2026 4 p.m. Backbench Business Committee - Oral evidence Subject: Proposals for backbench debates At 4:15pm: Oral evidence Members of Parliament - Members of Parliament at House of Commons View calendar - Add to calendar |
|
Tuesday 27th January 2026 4 p.m. Backbench Business Committee - Oral evidence Subject: Proposals for backbench debates At 4:15pm: Oral evidence Members of Parliament - Members of Parliament at House of Commons View calendar - Add to calendar |
|
Tuesday 3rd February 2026 4 p.m. Backbench Business Committee - Oral evidence Subject: Proposals for backbench debates At 4:15pm: Oral evidence Members of Parliament - Members of Parliament at House of Commons View calendar - Add to calendar |
| Select Committee Documents |
|---|
|
Tuesday 6th January 2026
Oral Evidence - 2026-01-06 16:15:00+00:00 Proposals for backbench debates - Backbench Business Committee |
|
Tuesday 13th January 2026
Oral Evidence - 2026-01-13 16:15:00+00:00 Proposals for backbench debates - Backbench Business Committee |
|
Tuesday 20th January 2026
Oral Evidence - 2026-01-20 16:15:00+00:00 Proposals for backbench debates - Backbench Business Committee |
|
Tuesday 27th January 2026
Oral Evidence - 2026-01-27 16:15:00+00:00 Proposals for backbench debates - Backbench Business Committee |